Fig. 4
From: Epigenetic silencing of IGFBPL1 promotes esophageal cancer growth by activating PI3K-AKT signaling
IGFBPL1 inhibits the PI3K-AKT signaling pathway and suppresses human ESCC cell xenograft growth in mice. a Western blots showed that IGFBPL1 has an effect on the expression levels of PI3K, AKT, p-AKT, mTOR, p-mTOR, and MYC in KYSE150, KYSE410, and KYSE510 cells. Control, control vector; IGFBPL1, IGFBPL1 expression vector; β-actin, internal control; NC, siRNA negative control; siRNA, siIGFBPL1. b Growth curves represent cell viability evaluated by MTT assay in the control group, control plus NVP-BEZ235(100 nM) treatment group, siIGFBPL1 group, and siIGFBPL1 plus NVP-BEZ235 treatment group in KYSE510 cells. NC, control group; NC+, control plus NVP-BEZ235 treatment group; siRNA, siIGFBPL1; siRNA+, siIGFBPL1 plus NVP-BEZ235 treatment group. **p < 0.0 1, ***p < 0.001. c Western blots showed that IGFBPL1 has an effect on the expression levels of PI3K, AKT, p-AKT, mTOR, p-mTOR, and MYC in KYSE510 cells before and after NVP-BEZ235 treatment. NC, control group; NC+, control plus NVP-BEZ235 treatment group; siRNA, siIGFBPL1; siRNA+, siIGFBPL1 plus NVP-BEZ235 treatment group. d, e Represents tumors from KYSE150 cell xenografts in which IGFBPL1 is not expressed and IGFBPL1 is over-expressed. f Tumor growth curves of unexpressed IGFBPL1 and IGFBPL1 overexpressing KYSE150 cells. *p < 0.05. g Tumor weight at 28th day after inoculation of unexpressed IGFBPL1 and IGFBPL1 overexpressing KYSE150 cells in nude mice. Bars indicate mean of five mice. ***p < 0.001. h Images of hematoxylin and eosin staining show tumors from IGFBPL1 unexpressed and IGFBPL1 re-expressed KYSE150 xenograft mice. IHC staining reveals the expression levels of IGFBPL1, p-AKT, PI3K, and p-mTOR in IGFBPL1 unexpressed and IGFBPL1 re-expressed KYSE150 cell xenografts. Magnification, × 400